A new antimicrobial polyketide glycoside (1) and three known compounds, gilvocarcins H (2), V (3) and M (4) were isolated from the ethyl acetate extract of Streptomyces sp. QD01-2. The structure of (1) was established by spectroscopic analysis, X-ray single crystal diffraction and CD spectra. The new compound (1) showed potent antimicrobial activities against Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Candida albicans, with MIC values of 0.5-5.0 mM. Compound (1) also showed weak cytotoxicity against the MCF-7, K562 and P388 cell lines, with IC 50 values of 36, 39 and 45 mM, respectively. The results showed that the vinyl side chain helps to increase the cytotoxicity and antimicrobial activities of gilvocarcin-type glycosides. In addition, the NMR data of gilvocarcin H (2) were also reported for the first time. Keywords: antimicrobial activity; cytotoxicity; gilvocarcin HE; polyketide glycoside; Streptomyces INTRODUCTION Producing 13 000 bioactive metabolites described, cultured bacteria have been a prolific resource for drug discovery. 1 About 70% of these bioactive compounds have been isolated from cultured actinomycetes. 2 Among them, polyketide metabolites represent a major source for novel chemotherapeutics. 3 A particularly promising lead structure is gilvocarcin V (3), the prototype of a family of benzo[d]naphtha[1,2-b]pyran-6-one glycosides from Streptomyces spp. [4] [5] [6] [7] [8] Members of this family generally exhibit high antimicrobial and antitumor activities. 9 Structurally these gilvocarcintype polyketide glycosides differ in the nature of the sugar moiety and the side chain at C-8. [10] [11] [12] [13] [14] As part of our ongoing search for bioactive secondary metabolites from actinomycetes, 15-17 strain Streptomyces sp. QD01-2 was isolated from the 3-m-deep soil collected at Huiquan Square near Qingdao First Beach, China. Its secondary metabolites showed antibacterial activity against Staphylococcus aureus at a concentration of 100 mg ml -1 . And a series of peaks with the similar UV absorptions to those of gilvocarcin-type polyketide glycosides [4] [5] [6] [7] [8] were observed at l max 242, 274, 314 and 386 nm in the HPLC-UV profile (Supplementary Figure S7) . Chemical investigation resulted in the isolation of a new gilvocarcin, gilvocarcin HE (1), along with the known gilvocarcins H (2), 18 V (3), 5 and M (4) (Figure 1) . 5 New compound (1) displayed significant antimicrobial activities against S. aureus, Escherichia coli, Bacillus subtilis and Candida albicans, with MIC values of 0.5, 2.8, 5.0 and 3.6 mM, respectively. It also showed cytotoxicity against the MCF-7, K562 and P388 cell lines, with IC 50 values of 36, 39 and 45 mM, respectively.
INTRODUCTION
Producing 13 000 bioactive metabolites described, cultured bacteria have been a prolific resource for drug discovery. 1 About 70% of these bioactive compounds have been isolated from cultured actinomycetes. 2 Among them, polyketide metabolites represent a major source for novel chemotherapeutics. 3 A particularly promising lead structure is gilvocarcin V (3), the prototype of a family of benzo [d] naphtha [1,2-b] pyran-6-one glycosides from Streptomyces spp. [4] [5] [6] [7] [8] Members of this family generally exhibit high antimicrobial and antitumor activities. 9 Structurally these gilvocarcintype polyketide glycosides differ in the nature of the sugar moiety and the side chain at C-8. [10] [11] [12] [13] [14] As part of our ongoing search for bioactive secondary metabolites from actinomycetes, [15] [16] [17] strain Streptomyces sp. QD01-2 was isolated from the 3-m-deep soil collected at Huiquan Square near Qingdao First Beach, China. Its secondary metabolites showed antibacterial activity against Staphylococcus aureus at a concentration of 100 mg ml -1 . And a series of peaks with the similar UV absorptions to those of gilvocarcin-type polyketide glycosides [4] [5] [6] [7] [8] were observed at l max 242, 274, 314 and 386 nm in the HPLC-UV profile (Supplementary Figure S7) . Chemical investigation resulted in the isolation of a new gilvocarcin, gilvocarcin HE (1), along with the known gilvocarcins H (2), 18 V (3), 5 and M (4) (Figure 1 ). 5 New compound (1) displayed significant antimicrobial activities against S. aureus, Escherichia coli, Bacillus subtilis and Candida albicans, with MIC values of 0.5, 2.8, 5.0 and 3.6 mM, respectively. It also showed cytotoxicity against the MCF-7, K562 and P388 cell lines, with IC 50 values of 36, 39 and 45 mM, respectively. Table 1 , Supplementary Figure S8 ).
RESULTS

Physico-chemical properties
Biological activity
The antimicrobial activities of these four compounds were evaluated by an agar dilution method. 20 The results showed that compounds 1-4 displayed antimicrobial activity against S. aureus, B. subtilis, E. coli and C. albicans (Table 2) , while compounds 1-4 were inactive against Aerobacter aerogenes and Pseudomonas aeruginosa (MIC4100 mM). Compounds (1) and (3) are more active than compounds (2) and (4), and (2) is more active than (4), indicating that both unsaturation and oxidation at the side chain result in an increase of antimicrobial activities of gilvocarcin-type glycosides.
The cytotoxicities of compounds 1-4 were also evaluated against MCF-7, K562 and P388 cell lines by the MTT method. 21 The results showed that compound (3) was the most active against the tested tumor cell lines, indicating that the vinyl side chain might have an important role in cytotoxicity of gilvocarcin-type glycosides (Table 3) .
Structure determination
Compound (1) Figure  S4 ) spectra as two methoxy carbons, two methyl carbons, five olefinic methine carbons, six oxygenated methine carbons, 11 olefinic quaternary carbons (four oxygenated) and one conjugated ester carbonyl carbon. These NMR data were very similar to those of gilvocarcin V, 5 further indicating the nature of gilvocarcin-type Figure S5) . Furthermore, obvious downfield shifts for C-8, C-6a and H-7 and upfield shifts for C-7 and H-9 were observed between (1) and gilvocarcin V. These observations suggested that compound (1) Figure S6 ). Single crystal X-ray diffraction analysis further confirmed the structure (Figure 3) , and its relative configuration was also resolved. As the absolute configuration of gilvocarcin V had been resolved by total synthesis, 19 the absolute configuration of fucose moiety of compound (1) could be deduced from the comparison of CD spectra between (1) and gilvocarcin V (3). Thus, the CD curves of (1) (Figure 4 ), indicating D-fucose (that is, 1 0 R, 2 0 R, 3 0 R, 4 0 S, 5 0 R). According to the X-ray crystal structure, the absolute configuration of C-13 was therefore determined as S-. Consequently, the structure of gilvocarcin HE (1) was elucidated to be 4-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(1S-hydroxyethyl) tetrahydrofuran-2-yl]-1-hydroxy-8-(1S-hydroxyethyl)-10,12-dimethoxy-6H-dibenzo[c,h]chromen-6-one.
METHODS
General experimental procedures
Optical rotations were obtained on a JASCO P-1020 digital polarimeter (JASCO Corporation, Tokyo, Japan). IR spectra were recorded using a Bruker model. UV spectra were recorded on Beckman DU 640 spectrophotometer (Beckman, Brea, CA, USA). 1 H, 13 C NMR and DEPT spectra and 2D-NMR were recorded on a JEOL JNM-ECP 600 spectrometer (JEOL Ltd., Tokyo, Japan) using TMS as internal standard, and chemical shifts were recorded as d values. ESI-MS was measured on a Q-TOF Ultima Global GAA076 LC mass spectrometer (Waters, Milford, MA, USA). Semi-preparative HPLC was performed using an ODS column (YMC-pack ODS-A, 10 Â 250 mm 2 , 5 mm, 4 ml min -1 ).
Strain
The Streptomyces sp. QD01-2 was isolated from a 3-m-deep soil sample collected at Huiquan Square near Qingdao First Beach, Shandong province of China. It was identified according to its morphological characteristics and The CD curve of (1) (blue) and (3) (red). A full color version of this figure is available at The Journal of Antibiotics journal online.
Streptomyces sp and polyketide glycoside J Hou et al 16S rRNA sequences. The voucher specimen is deposited in our laboratory at À80 1C. The working strain was prepared on a Gause's Synthetic Agar medium and stored at 4 1C.
Fermentation
The Streptomyces sp. QD01-2 was incubated on a rotary shaker (180 r.p.m.) at 28 1C for 8 days in 500 ml Â 200 conical flasks each containing 150 ml of a liquid medium composed of glucose (3 g), beef extract (0.45 g), amidulin (1.5 g), yeast extract (1.5 g), corn steep liquor (0.15 g), NaCl (0.075 g), MgSO 4 (0.075 g), KH 2 PO 4 (0.075 g), CaCO 3 (0.3 g), adjusting its pH to 7.0.
Extraction and isolation
The fermented whole broth (80 l) was extracted three times with an equal volume of EtOAc to give an ethyl acetate solution. The ethyl acetate solution was concentrated in vacuo to give a crude extract (32 g). The crude extract was then subjected to vacuum liquid chromatography using step gradient elution with CH 2 Cl 2 -MeOH (100 : 0, 100 : 1, 50 : 1, 30 : 1, 20 : 1, 10 : 1) to give six fractions (fractions 1-6) based on TLC properties. Fraction 4 (2 g) was washed with MeOH to give insoluble yellow amorphous powder. The yellow amorphous powder was further separated by semi-preparative HPLC (68% MeOH-H 2 O) to yield (1) (4 mg, t R 10.2 min) and (2) (2mg, t R 6.4 min). Fraction five (5 g) was washed with MeOH to give insoluble yellow amorphous powder that was further separated by semi-preparative HPLC (60% CH 3 CN-H 2 O) to yield (3) (10 mg, t R 11.5 min) and (4) (18 mg, t R 9.1 min).
X-ray structure determination of (1) Compound (1) 
Antimicrobial assay
The antimicrobial activities against E. coli, B. subtilis, A. aerogenes, P. aeruginosa, S. aureus and C. albicans were evaluated by an agar dilution method. 20 The tested strains were cultivated on LB agar plates for bacteria and on YPD agar plates for C. albicans at 37 1C. The four compounds and positive controls were dissolved in MeOH at different concentrations from 50 to 0.05 mg ml -1 by the continuous 2-fold dilution methods. A 10 ml quantity of test solution was absorbed by a paper disk (5 mm diameter) and placed on the assay plates. After 12 h incubation, zones of inhibition (mm in diameter) were recorded. The MICs were defined as the lowest concentration at which no microbial growth could be observed. Ciprofloxacin was used as the positive control for E. coli, B. subtilis, S. aureus, P. aeruginosa and E. aerogenes with MIC values of 0.9, 1.2, 0.3, 1.9 and 3.7 mM, respectively. Ketoconazole was used as the positive control for C. albicans with MIC values of 0.5 mM.
Cytotoxicity assay
The four compounds were evaluated for cytotoxic effects on MCF-7, K562 and P388 cell lines using the MTT method. 21 In the MTT assay, cell lines were grown in broth RPMI-1640 supplemented with 10% FBS under a humidified atmosphere of 5% CO 2 and 95% air at 37 1C. Two hundred microliter of cell suspensions at a concentration of 5 Â 10 4 cells ml À1 were plated in 96-well microtiter plates and incubated for 24 h. Then, 2 ml of the test solutions (in DMSO) were added to each well and further incubated for 72 h. The MTT solution (20 ml, 5 mg ml -1 in IPMI-1640 medium) was then added to each well and incubated for 4 h. Old medium containing MTT (150 ml) was then gently replaced by DMSO and pipetted to dissolve any formazan crystals formed. Absorbance was then determined on a Spectra Max Plus plate reader (Molecular Devices, Sunnyvale, CA, USA) at 540 nm. The IC 50 values were obtained using the Bliss method.
